This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

MMI advances prostrate cancer clinical trials

Written by Lautaro Vargas
Friday, 13 March 2009

Cancer drug developer, Medical Marketing International (MMI), is pushing forwards with plans to take its commercial prostate cancer vaccine (GVX 3322) into Phase II clinical trials following the successful completion of preclinical equivalence studies.

The Cambridge companys share price rose 6.1 per cent to 6.5p a share following the announcement that it is now in discussions with leading clinical oncologists to define the key parameters for a prostate cancer trial.

MMIs chemotherapy work has also advanced significantly, with pre-clinical studies on how its ruthenium compound ONCO 4417 kills cancer cells hinting that a number of novel cancer targets may be possible.

http://www.businessweekly.co.uk/2009031334670/life-sciences/mmi-advances-prostrate-cancer-clinical-trials.html

I read that this swine flu could effect 10 million people in the UK and hundreds could die if not treated.

mitzy suggest you stop reading the Beano!

Sky news said so.. it must be true..!

Sky journos bringing you news of fresh disasters!

Anna Botting is the worst ever thanks very much indeed..!

Some good buying here today. Picked up a few at 4p and looks for a run back to 6p imo on the chart.

Hope your right this time.